H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect onTGF-β1activation. H-Leu-Ser-Lys-Leu-OH, binding withKRFK(HY-P3970), can block the signal transduction ofTGF-β1, and prevent the progression of hepatic damage and fibrosis^[1].

TGF-β1^[1]

H-Leu-Ser-Lys-Leu-OH (LSKL) 也可以阻断 TSP-1 对 TGF-β1 的激活，并降低 KRFK 肽对 TGF-β1 的激活^[1]。

H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; 腹腔注射; 每日给药，共 4 周; 并伴随着 DMN 的处理) 能够保护二甲基亚硝胺 (DMN) 处理 (10 mg/kg; 腹腔注射; 每周连续3天给药, 共 4 周) 导致的大鼠肝萎缩。H-Leu-Ser-Lys-Leu-OH 还可以预防肝损伤和纤维化的进展^[1]。

459.58

C₂₁H₄₁N₅O₆

162559-45-7

LSKL

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.